Three branches of the American Association for Laboratory Animal Science (AALAS), the New Jersey Branch, the Delaware Valley Branch and the Metro New York Branch, join together each year to sponsor the TriBranch Symposium. The theme of this year’s TriBranch Symposium, held 11–13 June in Atlantic City, NJ, was R5: Reduction, Refinement, Replacement, Respect andContinueContinue reading “2012 TriBranch Symposium”
Category Archives: conferences
Experimental Biology 2012
Six scientific societies came together in San Diego, CA, in April for their joint scientific sessions and annual meetings, creating a ‘super-conference’ called Experimental Biology 2012. The American Association of Anatomists (AAA), the American Physiological Society (APS; celebrating its 125th anniversary this year), the American Society for Biochemistry and Molecular Biology (ASBMB), the American SocietyContinueContinue reading “Experimental Biology 2012”
New devices for CTO revascularization
From bacterial collagenase to laser wires, presenters at the Fourth International Chronic Total Occlusion (CTO) Summit discussed their experience with several new modalities developed specifically for treating challenging CTOs. J. Interv. Cardiol. 20, 402-405 (2007). view full text (login required)
Researchers discuss advances in retrograde approach to crossing CTOs
Presenters at the Fourth International Chronic Total Occlusion (CTO) Summit held in February reported the latest advances in using the retrograde approach to cross CTOs. This technique has been largely developed and honed by Japanese researchers as an alternative to the standard antegrade approach. Proceedings of TCT 4, 10-13 (2007). view PDF
Cell therapy for congestive heart failure moves to clinical trials
Presenters at the Third International Conference on Cell Therapy for Cardiovascular Diseases reported the most recent clinical trial results of cell-based treatments for congestive heart failure involving both bone marrow- and muscle-derived progenitor cells. Proceedings of TCT 4, 14-16 (2007). view PDF
Global frontiers in cell-based therapies explored
Investigators at the Third International Conference on Cell Therapy for Cardiovascular Diseases discussed the latest advances in 2 areas at the forefront of cardiovascular cell treatments: angiogenesis/tissue repair, and engineered cardiac tissue. Proceedings of TCT 4, 15-17 (2007). view PDF
Hybrid cell technologies show promise in treating ischemia
By combining cell therapy techniques with tissue engineering—two approaches that have produced mixed results on their own—researchers are attempting to effect myocardial repair after a heart attack, as well as interrupt the cellular cascade that leads from myocardial infarction (MI) to eventual heart failure. Each approach has its strengths and drawbacks, researchers reported at theContinueContinue reading “Hybrid cell technologies show promise in treating ischemia”
PFO closure for migraines remains an open question
Though greatly anticipated, results of the MIST (Migraine Intervention with STARFlex Technology) trial, presented during the Innovation in Intervention Summit at the annual meeting of the American College of Cardiology in March 2006, failed to prove the benefits of patent foramen ovale (PFO) closure in migraine prevention. The MIST results add to the body ofContinueContinue reading “PFO closure for migraines remains an open question”
Nonautologous cells progress toward clinical trials
Although nonautologous cells are increasingly considered the best cell-based method for treating cardiovascular disease, their therapeutic application has thus far been hindered by a lack of knowledge concerning their immunogenicity, ideal conditions for differentiation, and mechanisms for introducing them into damaged hearts. Presentations at the Second International Conference on Cell Therapy for Cardiovascular Disease inContinueContinue reading “Nonautologous cells progress toward clinical trials”
State of the art of CTO revascularization
Since the First International Chronic Total Occlusion Summit in 2004, advances in tools and techniques and in patient selection and safety have improved the potential for successful chronic total occlusion (CTO) treatment. This progress is reflected in the live case success rates for the three CTO Summits. Proceedings of TCT 3, 12-14 (2006). view PDF
Fluent in Science 